Advisory Board

Andrew Kay

Scientific Advisory Board

Andrew Kay, BPharm Hons has extensive board and international business experience both in Pharmaceutical Biotech and major Pharmaceutical companies. Chairman CaNDy Therapeutics, NeRRe Therapeutics, and Blueberry Therapeutics, Senior Advisor HealthCap VC. Previously CEO and board member of Algeta (top 25 biotech, oncology, market cap $2.9 Billion) with R&D/manufacturing in Europe and co-promotion in the USA. Previous Chairman of Wilson Therapeutics (successfull $855Mn exit). Kay’s previous roles include Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots. International career spans CEO, country/ business management, marketing, sales, medical/regulatory, manufacturing. Assignments include roles in the USA, UK, Italy, Switzerland and Scandinavia. Wide range of major licensing deals and product launch experience covering the major therapeutic areas and 8 blockbuster launches.

Wide range of major licensing deals and product launch experience covering the major therapeutic areas and 8 blockbuster launches.

Gregory Gores

Scientific Advisory Board

Professor, Executive Dean for Research across the Mayo enterprise Gregory J. Gores, MD, is a senior academician with broad contributions to research, clinical practice, education and leadership. His research contributions include sustained federal funding for more than 25 years, over 500 publications, an H-index of 103 and over 30,000 citations. Based on these accomplishments, he was appointed as a Distinguished Mayo Investigator. His clinical focus on cholangiocarcinoma and hepatobiliary neoplasia has led to pioneering work employing novel protocols for cholangiocarcinoma combined with liver transplantation. His leadership positions include past presidency of the American Association for the Study of Liver Disease and the International Liver Cancer Association. He is a current member of the American Gastroenterological Association Governing Board. He has also served as chair of the Gastroenterology and Hepatology Division at Mayo Clinic Rochester, medical director of the Liver Transplant Program.

Jesper B. Andersen

Scientific Advisory Board

Associate Professor, MSc PhD Affiliation Jesper B. Andersen is a lead cancer researcher in the field of translational medicine with 12 years of experience working in the United States. He has published more than 80 seminal research papers in the field of the molecular pathogenesis of Hepato-Pancreato-Biliary (HPB) cancers. In 2014, he established the Andersen group at Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Department of Health and Medical Sciences at University of Copenhagen, Denmark.
The Andersen group is focusing on understanding the molecular tumor heterogeneity, how genome alterations are involved in drug resistance and patient stratification as well as utilizing disease models for testing new therapies. He is the co-founder of the European Network for the Study of Cholangiocarcinoma (ENSCCA), member of the management committee for the EU COST Action ”European Cholangiocarcinoma Network”, member of the International Cholangiocarcinoma Research Network (ICRN) under the US Cholangiocarcinoma Foundation, and part of the steering committee in the Global Cholangiocarcinoma Alliance (GSA).

Jo Klaveness

Scientific Advisory Board / Research Partner

MSc Pharm. University of Oslo, Professor Jo Klaveness is a professor of medical chemistry at the University of Oslo’s School of Pharmacy and the founder of Drug Discovery Laboratory AS. He has a doctoral degree and a master’s degree in organic chemistry as well as an MSc Pharm. in pharmaceutical chemistry from the University of Oslo. He has held several positions in Nycomed, including as project manager and head of the R&D organisation, and served in several boards of directors, including for Pronova Biopharma ASA and Omegatri AS. Klaveness is the inventor of more than 160 patent families related to several pharmaceutical products that are on the market.

Kari Rødås

Scientific Advisory Board

M.Science Kari Rødås is an experienced enterprise architect, with focus of effective and efficient processes and digital championships. Rødås has strong experience  within Master Data Management,  Data Quality and IT solutions. She is currently Enterprise Architect at Ruter AS and former Head of Master Data Management Norway/Insights and Data at Capgemini and has a broad international network and experience from global projects. As a business architect Rødås is balancing processes, information architecture and integration architecture against best practices and frameworks both within system development and analyzing/statistics/prediction. Rødås´ key competences includes the intersection of business understanding and technology.

Audun N. Øksendal

Scientific Advisory Board

Dr. Philos Audun Øksendal is a former special adviser in biotechnology with the Research Council of Norway, and was CEO of Medinnova, now Inven2, which was responsible for medical innovation based at Oslo University Hospital. He is a Dr. Philos. with a doctorate in basic cardiology, and he worked for Nycomed Imaging for 15 years in different management functions in the areas of research, strategic planning and international marketing. He was responsible for the merger of the marketing departments of the Norwegian company Nycomed Imaging and the English company Amersham and was director of marketing for Europe and Asia. He is currently engaged in consultancy in the field of life sciences.

Per Walday


Per Walday, PhD (physiology) is CEO at PCI Biotech ASA and formerly had the position as Global Head of Project Management at GE Healthcare with responsibility for project management of all pharmaceutical product development. He has had former manager positions in Nycomed Imaging/Amersham Health developing mainstream diagnostic drugs found in the market today. Dr. Walday has a broad international network and is experienced with business development and approvals of new products in the international scene of the pharmaceutical industry. He serves a mentor for the CEO of Seald, Tove Cecilie Viebe.

Stig Nordal


Nordal is an attorney and a partner in SANDS, one of the largest law firms in Norway. He heads the Technology Group in SANDS, and works primarily with startups and scaleups within the technology sector – ict, tmt, med-tech, life science, biotech – advising in funding processes, ownership structures, transactions, both nationally and internationally, incentive schemes, business modelling and strategy. He also has broad experience from working with technology investors, business angel funds and venture funds within the tech-sector, as well as being director of various technology startups and technology funds. Nordal holds a master degree in innovation, business modelling and entrepreneurship from the Norwegian Business School BI, in addition to his law degree from University of Oslo. Nordal has worked with the US based law firm Perkins Coie in Silicon Valley, California, US in 2015-2016, in order to facilitate Norwegian companies establishing and seeking funding in the US in cooperation with US attorneys and the financial environment in Silicon Valley. He serves a mentor for the CEO of Seald, Tove Cecilie Viebe.